stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Current ratio
BridgeBio Pharma, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 2.1×, down 0.7× from fiscal 2025 (2.8×). Over the past ten years it has ranged from 2.8× (fiscal 2025) to 13.7× (fiscal 2018) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.8× | (40.65%) |
| FY2024 | 4.7× | 40.58% |
| FY2023 | 3.3× | (26.54%) |
| FY2022 | 4.5× | (31.32%) |
| FY2021 | 6.6× | (2.08%) |
| FY2020 | 6.7× | (28.63%) |
| FY2019 | 9.4× | (31.10%) |
| FY2018 | 13.7× | 26.81% |
| FY2017 | 10.8× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.1× | 70.46% |
| Jun 2026 | 1.2× | (19.28%) |
| Mar 2026 | 1.5× | (45.11%) |
| Dec 2025 | 2.8× | (28.52%) |
| 26 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | 11.1× |
| SMMT Summit Therapeutics PLC compare | 7.0× |
| TECH Bio-Techne Corp compare | 4.5× |
| HALO Halozyme Therapeutics, Inc. compare | 3.9× |
| EXEL Exelixis, Inc. compare | 3.2× |
| ASND Ascendis Pharma A/S compare | 3.0× |
| BMRN BioMarin Pharmaceutical Inc. compare | 2.4× |
| BBIO BridgeBio Pharma, Inc. | 2.1× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement